There are various behavioral interventions and electrical devices that are useful in treating the involuntary movements or neuropsychiatric symptoms of Tourette Syndrome, but often adjunctive pharmacological therapies are necessary to achieve good outcomes. The next New Jersey Center for Tourette Syndrome & Associated Disorders (NJCTS) Wednesday Webinar – “Medication Management for Tics and Tourette Syndrome” – on May 8 will explain the biological rationale for using medications for tics and TS, the various types of drugs that have shown to be beneficial, and discuss the risks and benefits of medication therapies.
This webinar, which will be presented by Dr. Mark Mintz, Psy.D., is for professionals, therapists, and persons and their families dealing with Tourette and associated disorders such as OCD, ADHD, anxiety, depression and mood disorders. Dr. Mintz is the president and CEO of The Center for Neurological and Neurodevelopmental Health and the Clinical Research Center of New Jersey in Gibbsboro. More information is available by visiting www.thecnnh.org.
Dr. Mintz also attended medical school at the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, performed his pediatric residency training at the Albert Einstein College of Medicine/Montefiore Medical Center, and completed a Pediatric Neurology fellowship at New Jersey Medical School. He is triple-Board Certified in Child Neurology, Pediatrics and Neurodevelopmental Disabilities.
NJCTS launched the monthly Wednesday Webinar series, which draws an audience from 48 states and 13 countries, in 2008. The series, offered at no cost to participants, features online seminars for parents, educators and professionals on topics of interest to the TS and associated disorders community. Professional development credits are given upon verification of attendance and completion of an exit survey. Credits are distributed by mail one week after the webinar. To register for this webinar, please click here. To view and download past NJCTS webinars, please click here.